Search research articles
Contact Us
Filters
Showing results (151-160 of 227) with videos related to
Page
of 23
Sort By:
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
Joanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 227) with videos related to
Sort By:
Page
of 23
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
Joanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Page
of 23